Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML i soform I and induces its SUMO-independent degradation

Journal of Virology

Volumn 86, Issue 20, 2012, Pages 11209-11222

  Cuchet Lourenço, Delphine ^a   Vanni, Emilia ^a   Glass, Mandy ^a   Orr, Anne ^a   Everett, Roger D ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; SUMO PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE ICP0; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN TARGETING; TWO HYBRID SYSTEM;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CRICETINAE; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; NUCLEAR PROTEINS; PROTEIN ISOFORMS; PROTEOLYSIS; SUMOYLATION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VERO CELLS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 1;

EID: 84869025216     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01145-12     Document Type: Article

References (60)

1. Bernardi R, Pandolfi PP. 2003. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22:9048-9057.
2. Bernardi R, Pandolfi PP. 2007. Structure, dynamics, and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell. Biol. 8:1006-1016.
3. Bischof O, et al. 2002. Deconstructing PML-induced premature senescence. EMBO J. 21:3358-3369.
4. Boddy MN, Howe K, Etkin LD, Solomon E, Freemont PS. 1996. PIC 1, a novel ubiquitin-like protein which interacts with thePMLcomponent of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 13:971-982.
5. Boutell C, et al. 2011. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 7:e1002245. doi:10.1371/journal.ppat.1002245.
6. Boutell C, Orr A, Everett RD. 2003. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J. Virol. 77:8686-8694.
7. Boutell C, Sadis S, Everett RD. 2002. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76:841-850.
8. Brand P, Lenser T, Hemmerich P. 2001. Assembly dynamics of PML nuclear bodies in living cells. PMC Biophys. 3:3. doi:10.1186/1757-5036-3-3.
9. Canning M, Boutell C, Parkinson J, Everett RD. 2004. A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J. Biol. Chem. 279:38160-38168.
10. Chaurushiya MS, et al. 2012. Viral E3 ubiquitin ligase-mediated degradation of a cellular E3: viral mimicry of a cellular phosphorylation mark targets the RNF8 FHA domain. Mol. Cell 46:79-90.
11. Chelbi-Alix MK, de The H. 1999. Herpesvirus induced proteasomedependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18:935-941.
12. Condemine W, Takahashi Y, Le Bras M, de The H. 2007. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J. Cell Sci. 120:3219-3227.
13. Condemine W, et al. 2006. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 66:6192-6198.
14. Cuchet-Lourenco D, et al. 2011. SUMO pathway-dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 7:e1002123. doi:10.1371/journal.ppat.1002123.
15. Cuchet D, et al. 2011. PML isoforms I and II participate in PMLdependent restriction of HSV-1 replication. J. Cell Sci. 124:280-291.
16. Davido DJ, von Zagorski WF, Lane WS, Schaffer PA. 2005. Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function. J. Virol. 79:1232-1243.
17. Dellaire G, Bazett-Jones DP. 2004. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays 26:963-977.
18. Drane P, Ouararhni K, Depaux A, Shuaib M, Hamiche A. 2010. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 24:1253-1265.
19. Everett RD, Chelbi-Alix MK. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
20. Everett RD, Earnshaw WC, Findlay J, Lomonte P. 1999. Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J. 18: 1526-1538.
21. Everett RD, et al. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
22. Everett RD, Lomonte P, Sternsdorf T, van Driel R, Orr A. 1999. Cell cycle regulation of PML modification and ND10 composition. J. Cell Sci. 112:4581-4588.
23. Everett RD, Meredith M, Orr A. 1999. The ability of herpes simplex virus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific protease contributes to its roles in the activation of gene expression and stimulation of virus replication. J. Virol. 73:417-426.
24. Everett RD, et al. 1997. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:1519-1530.
25. Everett RD, Murray J, Orr A, Preston CM. 2007. Herpes simplex virus type 1 genomes are associated with ND10 nuclear substructures in quiescently infected human fibroblasts. J. Virol. 81:10991-11004.
26. Everett RD, Orr A, Elliott M. 1991. High-level expression and purification of herpes simplex virus type 1 immediate-early polypeptide Vmw110. Nucleic Acids Res. 19:6155-6161.
27. Everett RD, Orr A, Preston CM. 1998. A viral activator of gene expression functions via the ubiquitin-proteasome pathway. EMBO J. 17:7161-7169.
28. Everett RD, Parada C, Gripon P, Sirma H, Orr A. 2008. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82:2661-2672.
29. Everett RD, et al. 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80:7995-8005.
30. Fu L, et al. 2005. Nuclear aggresomes form by fusion of PML-associated aggregates. Mol. Biol. Cell 16:4905-4917.
31. Gripon P, et al. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 99:15655-15660.
32. Ishov AM, et al. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234.
33. Jamieson DR, Robinson LH, Daksis JI, Nicholl MJ, Preston CM. 1995. Quiescent viral genomes in human fibroblasts after infection with herpes simplex virus type 1 Vmw65 mutants. J. Gen. Virol. 76:1417-1431.
34. Jensen K, Shiels C, Freemont PS. 2001. PML protein isoforms and the RBCC/TRIM motif. Oncogene 20:7223-7233.
35. Lafarga M, et al. 2002. Clastosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol. Biol. Cell 13:2771-2782.
36. Lallemand-Breitenbach V, et al. 2001. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193:1361-1371.
37. Lilley CE, et al. 2010. A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J. 29: 943-955.
38. Maul GG, Everett RD. 1994. The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0. J. Gen. Virol. 75:1223-1233.
39. Maul GG, Yu E, Ishov AM, Epstein AL. 1995. Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress. J. Cell Biochem. 59:498-513.
40. Meredith M, Orr A, Elliott M, Everett R. 1995. Separation of sequence requirements for HSV-1 Vmw110 multimerisation and interaction with a 135-kDa cellular protein. Virology 209:174-187.
41. Muller S, Dejean A. 1999. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73:5137-5143.
42. Nabetani A, Yokoyama O, Ishikawa F. 2004. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. J. Biol. Chem. 279:25849-25857.
43. Nagel CH, et al. Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation. J. Virol. 85:7644-7657.
44. Negorev D, Maul GG. 2001. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20:7234-7242.
45. Nguyen LA, et al. 2005. Physical and functional link of the leukemiaassociated factors AML1 and PML. Blood 105:292-300.
46. Parkinson J, Lees-Miller SP, Everett RD. 1999. Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J. Virol. 73:650-657.
47. Reineke EL, Kao HY. 2009. PML: an emerging tumor suppressor and a target with therapeutic potential. Cancer Ther. 7:219-226.
48. Salomoni P, Pandolfi PP. 2002. The role of PML in tumor suppression. Cell 108:165-170.
49. Schenk P, Ludwig H. 1988. The 65 K DNA binding protein appears early in HSV-1 replication. Arch. Virol. 102:119-123.
50. Shen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339.
51. Showalter SD, Zweig M, Hampar B. 1981. Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4. Infect. Immun. 34:684-692.
52. Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H. 1995. Two nuclear dot-associated proteins, PML and Sp100, are often coautoimmunogenic in patients with primary biliary cirrhosis. Scand. J. Immunol. 42:257-268.
53. Stow ND, Stow EC. 1986. Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate-early polypeptide Vmw110. J. Gen. Virol. 67:2571-2585.
54. Stuurman N, et al. 1992. A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J. Cell Sci. 101:773-784.
55. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. 2004. PML nuclear bodies and apoptosis. Oncogene 23:2819-2824.
56. Tavalai N, Stamminger T. 2009. Interplay between herpesvirus infection and host defense by PML nuclear bodies. Viruses 1:1240-1264.
57. Tavalai N, Stamminger T. 2008. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783: 2207-2221.
58. Vanni E, Gatherer D, Tong L, Everett RD, Boutell C. 2012. Functional characterization of residues required for the herpes simplex virus type-1 E3 ubiquitin ligase ICP0 to interact with the cellular E2 ubiquitinconjugating enzyme UBE2D1 (UbcH5a). J. Virol. 86:6323-6333.
59. Yao F, Schaffer PA. 1995. An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J. Virol. 69:6249-6258.
60. Zhong S, Salomoni P, Pandolfi PP. 2000. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:E85-E90